Patents by Inventor Young-Gyu Cho

Young-Gyu Cho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11306141
    Abstract: The present invention relates to an antibody against delta-like 1 homolog (Drosophila) (DLK1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, an antibody drug conjugate (ADC) comprising the same, a pharmaceutical composition for treating cancer, a composition for diagnosing cancer, and a chimeric antigen receptor (CAR) and a T-cell engager comprising the same.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: April 19, 2022
    Assignee: Y-BIOLOGICS INC.
    Inventors: Jung Chae Lim, Ji-Young Shin, Sunha Yoon, Sang Pil Lee, Yunseon Choi, Jisu Lee, Young-Gyu Cho, Seok Ho Yoo, Yeung chul Kim, Si Hyung Lee, Jae Eun Park, Youngja Song, Gi Sun Baek, Bum-chan Park, Young Woo Park
  • Patent number: 11248048
    Abstract: Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: February 15, 2022
    Assignee: Y-BIOLOGICS INC.
    Inventors: Jae Eun Park, Soo Young Kim, Hyun Mi Lee, Si Hyung Lee, Hyun Kyung Lee, Hye-Nan Kim, Jin Chui Youn, Bum-chan Park, Jung Chae Lim, Young-Gyu Cho, Young Woo Park
  • Publication number: 20210214432
    Abstract: The present invention relates to an antibody against delta-like 1 homolog (Drosophila) (DLK1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, an antibody drug conjugate (ADC) comprising the same, a pharmaceutical composition for treating cancer, a composition for diagnosing cancer, and a chimeric antigen receptor (CAR) and a T-cell engager comprising the same.
    Type: Application
    Filed: September 10, 2018
    Publication date: July 15, 2021
    Inventors: Jung Chae Lim, Ji-Young Shin, Sunha Yoon, Sang Pil Lee, Yunseon Choi, Jisu Lee, Young-Gyu Cho, Seok Ho Yoo, Yeung chul Kim, Si Hyung Lee, Jae Eun Park, Youngja Song, Gi Sun Baek, Bum-chan Park, Young Woo Park
  • Patent number: 10919966
    Abstract: Disclosed are an antibody to human programmed cell death-ligand 1 (PD-L1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer or infectious diseases containing the same.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: February 16, 2021
    Assignee: Y-BIOLOGICS INC.
    Inventors: Jae Eun Park, Soo A Choi, Jisu Lee, Hyun Mi Lee, Si Hyung Lee, Gi Sun Baek, Yeung Chul Kim, Bum-chan Park, Jung Chae Lim, Young-Gyu Cho, Young Woo Park
  • Publication number: 20190322750
    Abstract: Disclosed are an antibody to human programmed cell death-ligand 1 (PD-L1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer or infectious diseases containing the same.
    Type: Application
    Filed: August 7, 2017
    Publication date: October 24, 2019
    Applicant: Y-BIOLOGICS INC.
    Inventors: Jae Eun Park, Soo A Choi, Jisu Lee, Hyun Mi Lee, Si Hyung Lee, Gi Sun Baek, Yeung Chul Kim, Bum-chan Park, Jung Chae Lim, Young-Gyu Cho, Young Woo Park
  • Patent number: 10448662
    Abstract: The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 or a fragment thereof with a human antibody Fc region. Also provided are health functional foods containing a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 (delta-like 1 homolog) or a fragment thereof with a human antibody Fc region as an active ingredient.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 22, 2019
    Assignees: Y-Biologics Inc., Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Young Woo Park, Bum-chan Park, Bong-soo Cha, Yong Ho Lee, Jung Chae Lim, Young-gyu Cho, Joong Kyu Kim, Jae Eun Park, Seok Ho Yoo
  • Publication number: 20190248900
    Abstract: Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.
    Type: Application
    Filed: August 7, 2017
    Publication date: August 15, 2019
    Inventors: Jae Eun Park, Soo Young Kim, Hyun Mi Lee, Si Hyung Lee, Hyun Kyung Lee, Hye-Nan Kim, Jin Chul Youn, Bum-chan Park, Jung Chae Lim, Young-Gyu Cho, Young Woo Park
  • Publication number: 20170121380
    Abstract: The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 or a fragment thereof with a human antibody Fc region. Also provided are health functional foods containing a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 (delta-like 1 homolog) or a fragment thereof with a human antibody Fc region as an active ingredient.
    Type: Application
    Filed: October 28, 2016
    Publication date: May 4, 2017
    Inventors: Young Woo Park, Bum-chan Park, Bong-soo Cha, Yong Ho Lee, Jung Chae Lim, Young-gyu Cho, Joong Kyu Kim, Jae Eun Park, Seok Ho Yoo
  • Patent number: 8883134
    Abstract: The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: November 11, 2014
    Assignees: Handok Pharmaceuticals, Inc., Genexine, Inc.
    Inventors: Young Gyu Cho, Hye Jeong Shin, Woon Young Lee, Woo Ick Jang
  • Publication number: 20130217864
    Abstract: The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease.
    Type: Application
    Filed: October 19, 2011
    Publication date: August 22, 2013
    Applicant: HANDOK PHARMACEUTICALS CO., LTD.
    Inventors: Young Gyu Cho, Hye Jeong Shin, Woon Young Lee, Woo Ick Jang
  • Publication number: 20060116390
    Abstract: The present invention relates to new compounds useful for the treatment or prevention of hepatitis C, process for preparing them, and a composition for the treatment or prevention of hepatitis C comprising the compounds as an active ingredient.
    Type: Application
    Filed: June 9, 2004
    Publication date: June 1, 2006
    Inventors: Jae-Hong Lim, Joo-Yong Yoon, Jeong-Uk Song, Lee-Taek Sung, Sung-Pil Choi, Ho-Young Song, Jong-Yup Kim, Yong-Zu Kim, Young-Gyu Cho, Chang-Myung Kim, Won-Sup Kim, Seung-Wan Kang, Ji-Hyun Park